Glucagon-like receptor-1 agonists and impotence: A meta-analysis.

Two hundred thirty-seven men across seven heterogeneous studies is a thin base for pooled hormone estimates, and the confidence interval on total testosterone (MD 73.04, CI 16.91 to 129.17) is wide enough to span clinically trivial and clinically meaningful. The analysis is class-level, so semaglutide and tirzepatide appear as search terms rather than as separately estimated arms — nothing here supports an agent-specific effect. Weight loss itself raises testosterone in men with obesity, and the design cannot separate that from any direct drug effect. Directionally reassuring against the post-marketing impotence reports, but no more than that.